The Health Policy Partnership (HPP) is a specialist health policy consultancy established in 2016 and registered with the EU Transparency Register (registration number 223430420230-66). Its core mission is to provide innovative policy initiatives and evidence-based communications addressing complex challenges in healthcare systems across Europe. HPP focuses on rigorous research, expert synthesis of scientific and policy evidence, and inter-sectoral collaboration to influence meaningful changes in health policy and practice at the EU level.
HPP’s activity portfolio includes developing communication strategies and facilitating stakeholder engagement around pressing health issues, particularly in public health, cancer, heart failure, and respiratory diseases. It acts as the Secretariat for the Heart Failure Policy Network (HFPN), a multidisciplinary coalition involving patients, healthcare professionals, and policymakers working to improve outcomes for heart failure patients. For example, in April 2024, HPP organized an international online summit on heart failure featuring prominent EU policymakers.
The partnership also supports the European Heart Failure Mission aimed at eliciting EU political recognition and investment in heart failure. This initiative included high-profile policy events such as a 2024 Budapest event coinciding with the Hungarian EU presidency and direct advocacy with European Commissioners. Funding for these initiatives often comes from pharmaceutical companies like AstraZeneca and Roche Diagnostics.
HPP also supports the Lung Cancer Policy Network, which conducted roundtable discussions and webinars in 2024 focused on lung cancer screening and early detection across Central and Eastern Europe. These targeted events bring together patient advocates, clinicians, and researchers, and attract attendance and interest from Members of the European Parliament (MEPs).
Overall, HPP employs a pragmatic, evidence-driven approach to engage with EU institutions, leveraging strong relationships with MEPs and EU officials. Although none of its lobbyists currently hold EP accreditations, HPP dedicates part of its staff time to engaging directly with the European Parliament and Commission institutions. Its strategic involvement in policy networks and collaboration with pharmaceutical companies anchor its position as a leading health-focused lobby and consultancy operating in Brussels and across Europe
